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About 20% to 40% of patients with non-small cell lung cancer (NSCLC) will develop brain metastases during the
natural course of their disease. The prognosis for such patients is very poor with limited survival. In addition to the
standard whole brain radiation therapy (WBRT), some studies have shown that chemotherapy drugs and/or
epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) can improve the outcome of these patients.
Here, we report a stage IIIA patient who developed multiple brain metastases one year after operation. Oral
gefitinib with concurrent WBRT were given as first-line therapy. Complete response and a 50-month progression-
free survival (PFS) were obtained. Double dosage of gefitinib (500 mg per day) together with pemetrexed were
given as the second-line therapy after the patient developed new brain lesions and leptomeningeal metastasis
during the maintenance therapy of gefitinib. The PFS for the second-line therapy was six months. In total, the
patient obtained an overall survival of 59 months since the first diagnosis of brain metastases. Mutational analysis
showed a 15-nucleotide deletion and a missense mutation in exon 19 of the EGFR gene, and a missense mutation
at codon 12 of the K-ras gene. These underlying genetic changes might partially explain the long-term survival of
this patient after brain metastases when treated with concurrent or sequential therapies of EGFR-TKI, radiotherapy
and chemotherapy.
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MutationBackground
The reported incidence of brain metastasis (BM) in
patients with non-small cell lung cancer (NSCLC) ranges
from 20% to 40%. Multiple cerebral lesions are asso-
ciated with poor prognosis, and median overall survival
from the time of diagnosis is about three to six months.
Leptomeningeal metastasis (LM) of NSCLC is more fatal
than BM, without treatment, median survival ranges
from four to six weeks. The optimal treatment for such
patients is controversial, and the use of a combination of
radiotherapy, chemotherapy and EGFR-TKI remains un-
clear. The objective of the present case is to investigate* Correspondence: dr.mashenglin@gmail.com
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reproduction in any medium, provided the orthe response to gefitinib and pemetrexed in such a
patient.Case presentation
In June 2005, a 52-year-old man was admitted to our
hospital after the detection of a mass in his right lung in
a routine physical examination. He was a non-smoker
and did not have any disease-related symptoms, such as
cough, dyspnea or emptysis. Chest computerized tomog-
raphy (CT) scan revealed a mass of 2.5 cm × 2.0 cm in
size in the right upper lobe with ipsilateral, multiple
bulky hilar and mediastinal lymph nodes. Abdominal CT
scan, brain magnetic resonance imaging (MRI) and bone
emission computerized tomography (ECT) scan showed
no evidence of any distant metastasis. He was diagnosed
with adenocarcinoma by a CT-guided percutaneous cored. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Pathological findings showed irregular adenoid or papillary arrangement of cancer cells with invasion into the adjacent
tissues. Cells were rich in cytoplasma with obvious atypia and necrosis.
Figure 2 Magnetic resonance imaging (MRI) scan of the brain
found dilated ventricles, diffuse white matter atrophy, and a
metastatic mass about 1.5 cm in size in the right temporal
lobe.
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IIIA). Right upper lobectomy and systematic lymphade-
nectomy were performed after receiving informed con-
sent. No adhesions to the visceral pleura were
observed during the operation. Black swollen lymph
nodes were found surrounding the carina, main bron-
chus, as well as in the mediastinum. Complete resection
was achieved.
Pathologically, the primary lesion was 2.5 cm × 2.0 cm
in size in the right upper lobe. The final pathological re-
port showed adenocarcinoma with violations of the vas-
cular supply, negative bronchial resection margins, and
metastasis to hilar and mediastinal lymph nodes; 23/47
lymph nodes were positive (Figure 1). Immunohisto-
chemical staining showed the tumor was negative for
CgA, and positive for P53, PCNA, CK-L, CK-H, and NSE.
The patient received four cycles of adjuvant chemo-
therapy consisting of gemcitabine 1.0 g/m2 on day 1 and
day 8, and carboplatin AUC 5 on day 1, repeated every 3
weeks. Sequential adjuvant radiotherapy with the dosage
of 15 mV-X line DT 5000 cGy/25F irradiation on the
mediastinal area was given.
About one year after operation, asymptomatic multiple
cerebral metastases were detected during a routine fol-
low-up, without any other recurrent extracranial lesions.
As the patient refused systemic chemotherapy, we gave
him gefitinib, 250 mg per day, and concurrent whole
brain radiation therapy (WBRT) with the dosage of DT
4000 cGy/20F. Complete remission of the intracranial
lesions was found one month after radiation. The patient
continued to use gefitinib at 250 mg per day as mainten-
ance therapy. A progression-free survival (PFS) of 50.0
months was obtained.
In August 2010, more than five years after the oper-
ation, the patient was readmitted to our hospital because
of intense headache with nausea and vomiting. Emergent
brain MRI found dilated ventricles, diffuse white matter
atrophy, and also a metastatic mass about 1.5 cm in size
in the right temporal lobe (Figure 2). Chest CT scan
showed mild radiation pneumonitis without any evidenceof tumor recurrence. The intracranial pressure measured
by lumbar puncture was 220 mm H2O. Malignant cells
were found in the cerebrospinal fluid. The patient was
diagnosed with recurrent brain lesions and newly devel-
oped leptomeningeal metastases. A lumbar drainage cath-
eter was lined to relieve intracranial hypertension
symptoms. A double dosage of gefitinib of 250 mg twice a
day combined with pemetrexed 500 mg/m2 on day 1 every
3 weeks were suggested. After six cycles of pemetrexed,
no obvious changes were documented on the brain MRI
and chest CT, but the symptoms of intracranial hyper-
tension were completely relieved. The lumbar drainage
tube was removed, all dehydration agents were stopped,
and the performance score of the patient was improved
from 2 to 1. Then, the patient stopped pemetrexed and
went on with gefitinib single agent, 250 mg twice a day,
obtaining a time to progression of 6.0 months.
At the end of February 2011, about two months after
stopping pemetrexed, the patient had a recurrence of
headache with nausea and vomiting, and the perform-
ance score deteriorated quickly to 4. The dosage of gefi-
tinib was increased to 250 mg three times a day,
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nally died of pulmonary infection, hernia and cachexia
within three months.
The patient tolerated treatment well throughout the
whole treatment process. No obvious adverse reactions
were documented during the adjuvant chemotherapy and
radiotherapy, the palliative whole brain radiation therapy,
or the gefitinib treatment with a dosage of 250 mg per
day. Grade 1 acne-like rash on the face and back, and itch-
ing of the lower limbs were observed during the gefitinib
treatment with an increase in dosage to 500 mg or 750 mg
per day. Grade 4 neutropenia and thrombocytopenia were
documented in the first cycle of pemetrexed with the
standard dosage of 500 mg/m2. With a 20% reduction of
pemetrexed dosage and prophylactic use of granulocyte
colony-stimulating factor (G-CSF) and recombinant
human thrombopoietin (TPO), the patient completed the
following five cycles smoothly. Repeated grade 1 liver dys-
function was observed during the pemetrexed treatment.
The mutation analysis of related genes was carried out
in 2010 when the patient was diagnosed with recurrent
brain lesions and leptomeningeal metastases. Genomic
DNA was isolated from the tumor specimen obtained
from the operation five years earlier, after receiving
informed consent. The direct sequencing after PCR amp-
lification or pyrosequencing analysis were performed to
detect mutations in exons 19, 20 and 21 of the EGFR
gene, codon 12 and 13 of the K-ras gene, and codon
600 of the BRAF gene. A deletion of 15 nucleotides
(2240-2254del15; L747-S752del5) and a point mutation
(A2262T; K754I) in exon 19 of EGFR gene were detected
(Figure 3). Both exons 20 and 21 were wild type. A point
mutation of codon 12 (GGT→GAT; G12D) of the K-ras
gene was also identified, which led to an amino acid
change from glycine to aspartic acid (Figure 4). The
codon 600 of the BRAF gene was wild type.
Discussion
The prognosis for NSCLC patients with BM is poor,
with a natural history of about three to six months and aFigure 3 Mutational analysis of EGFR gene by direct sequencing. A de
(2240-2254del15; L747-S752del5) is indicated by a blue arrow. A point mut
red arrow.10% one-year survival rate [1]. Whole brain radiation
therapy (WBRT) is the standard treatment for BM
patients. Small molecules such as epidermal growth fac-
tor receptor-tyrosine kinase inhibitors (EGFR-TKIs) like
erlotinib, gefitinib and lapatinib have been demonstrated
to have the ability to cross the blood–brain barrier
(BBB). The use of chemotherapy for the treatment of
BM has been limited because of a presumed lack of ef-
fectiveness due to the BBB. However, in recent years,
some studies found that WBRT combined with systemic
chemotherapy or EGFR-TKIs could further improve the
outcome [2-4]. Kim et al. [3] reported an improvement
of median overall survival from 19.0 weeks to 58.1 weeks
in patients treated with WBRT and platinum-based
chemotherapy as compared to those with WBRT only. A
response rate of 81% and a disease control rate of 95%
were reported by Ma et al. [4] in their 21 NSCLC
patients with BM treated with concomitant WBRT and
gefitinib. The median PFS and median overall survival
(OS) were 10.0 months and 13.0 months, respectively.
However, in cases where the patients had tumor pro-
gression of intracranial lesions during or after comple-
tion of radiotherapy, no standard and effective treatment
could be recommended. Chemotherapy or targeted
agents could be used as an alternative.
The incidence of pulmonary adenocarcinoma is in-
creasing and it has become the leading subtype of lung
cancer according to recent statistics. Currently, peme-
trexed constitutes a commonly used standard second-
line treatment and first-line treatment option in patients
with metastatic nonsquamous cell lung cancer. Some
studies had shown the activity of pemetrexed for the
treatment of brain metastases with low toxicity [5-7].
Bearz et al. [6] reported an overall clinical benefit (stable
disease (SD) and partial response (PR)) and a cerebral
benefit of 63% and 68% respectively in 22 NSCLC
patients with brain metastases treated with pemetrexed
plus cisplatin. Patients were irradiation-naive or with
clear radiological evidence of cerebral progression after
brain radiotherapy and before pemetrexed treatment.letion of 15 nucleotides in exon 19 of the EGFR gene
ation in exon 19 of the EGFR gene (A2262T; K754I) is indicated by a
Figure 4 Mutational analysis of K-ras gene by pyrosequencing: a point mutation (arrow) in codon 12 (GGT→GAT; G12D) was detected.
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pemetrexed-cisplatin regimen was effective and well-
tolerated for 43 NSCLC patients with cerebral metasta-
sis. Cerebral, extracerebral and overall response rates
were 41.9%, 34.9% and 34.9% respectively. The disease
control rate was 72.1%. The median OS, median PFS
and median time to cerebral progression were 7.4
months, 4.0 months and 5.7 months. One patient even
had complete cerebral remission (1/43, 2.3%). The pos-
sible mechanisms of pemetrexed therapeutic activity in
brain metastasis might be as follows: (1) Molecular stud-
ies demonstrated that P-glycoprotein was a major con-
stituent of the BBB acting as an effective efflux
transporter protein. In contrast to primary cerebral
malignomas, brain metastases seemed to express less P-
glycoprotein leading to increased drug permeability of
the BBB. P-glycoprotein activity is usually measured in
the tumor cells and does not change the BBB permeabil-
ity of drugs. BBB is dependent on vascular not tumor
cells [8]. Therefore, lower levels of P-glycoprotein might
contribute to the effect of pemetrexed on NSCLC brain
metastasis. (2) Auxiliary use of dexamethasone and
mannitol during the treatment might increase BBB
permeability and cerebral concentrations of drugs.
(3) Pemetrexed might upregulate the local bradykinin
B2 receptors and affects the secretion of bradykinin
to play a therapeutic role, although the mechanism is
unclear [9].
In addition to chemotherapy drugs, oral EGFR-TKIs
had shown remarkable efficacy in NSCLC patients with
brain metastases [10-12]. The EGFR-TKIs have excellent
cell penetration of the BBB because of its chemical
structure and low molecular weight. In 2003, Cappuzzo
et al. [10] first reported one complete and three partial
responses after three months of single gefitinib treat-
ment in four NSCLC patients with pretreated brain me-
tastasis. Thereafter, more studies presented further
evidence of gefitinib efficacy in patients with brain andleptomeningeal metastasis [13,14]. However, it was
reported that 57% patients had central nervous system
(CNS) relapse during the gefitinib therapy, while there
was no progression in extracerebral lesions. No standard
treatment could be recommended for such patients.
Jackman et al. [15] reported erlotinib-refractory lepto-
meningeal metastases from lung adenocarcinoma
responds to high-dose gefitinib treatment, and high-
lighted that CNS metastases did not always harbor re-
sistance mutations and suggested they retained erlotinib/
gefitinib sensitivity if therapeutic drug concentrations
were achieved. It was reported by Clarke et al. [16] that
in patients developing meningeal metastasis during TKIs
(erlotinib) treatment, the intermittent or pulsatile high-
dose administration (1000 to 1500 mg/week) achieved a
higher cerebrospinal fluid concentration than standard
dosing, and successfully controlled LM in this patient.
Our patient developed multiple brain metastases one
year after the operation. Whole brain radiation therapy
combined with oral gefitinib was the first-line therapy,
and the patient had great benefit with a PFS of more
than four years. Double dosage of gefitinib (500 mg per
day) combined with pemetrexed was the second-line
therapy after the patient developed new brain lesions
and leptomeningeal metastases, despite adequate control
of the lung cancer outside the CNS. The PFS for the
second-line treatment of gefitinib and pemetrexed was
6.0 months. The patient had a total OS of about five
years after the first diagnosis of brain metastasis, which
was extremely good as compared with survival data
reported in the literature. The gefitinib treatment was ef-
fective for more than four years for first-line and effect-
ive again for six months with a double dosage together
with pemetrexed for second-line treatment, which might
be related to the sensitivity mutations detected in exon
19 of the EGFR gene, a deletion mutation of 15 nucleo-
tides and a missense mutation downstream [17,18]. Co-
existence of EGFR and K-ras mutations was seldom
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mutated patients [19]. Retrospective investigations of K-
ras mutational status implied that K-ras mutation might
be a negative predictor of response and a mechanism of
de novo resistance to EGFR-TKI, even in patients with
EGFR mutations [19-21]. However, small sample sizes as
a result of low prevalence of K-ras mutations and the
low rate of tumor sample collection have limited the
strength of these analyses. And in this case, the role of
the missense mutation detected at codon 12 of the K-ras
gene remains to be elucidated. To a certain extent, it
might contribute to the limited PFS and OS after the pa-
tient developed new brain lesions and leptomeningeal
metastasis. Although, both gefitinib and pemetrexed had
shown some therapeutic effects in patients with brain or
leptomeningeal NSCLC metastasis, the effect of the
combination of these two drugs remained uncertain. It
was even hard to distinguish whether the patient bene-
fited from gefitinib or pemetrexed. Learning from this
case, the combination therapy of pemetrexed and gefiti-
nib might have a better prospect. Prospective studies
with a large sample should be carried out to further clar-
ify the efficiency and underlying mechanisms.
Conclusion
In conclusion, the concurrent or sequential use of radio-
therapy, chemotherapy and EGFR-TKI might have a bet-
ter prospect in EGFR-mutated NSCLC patients with
brain metastasis and/or leptomeningeal metastasis.
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